| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
Significant increases in MV4-11 or MOLM-13 cells are caused by AC-4-130 (0.1-100 μM; 72 hours) in a formulation- and time-dependent manner [1]. Cell induction cycle is triggered by AC-4-130 (2, 5 μM; 72 hours), which causes a decrease in S or G2/M phase cells and an increase in G0/G1-induced cells [1]. The cytoplasm and nucleus of AC-4-130 (0.5-2; 24 hours) cells displayed decreased pY-STAT5 levels. Primary human AML cells' ability to proliferate and develop clonally was significantly suppressed by AC-4-130-mediated suppression of STAT5, whereas healthy CD34+ cells are less susceptible [1].
|
|---|---|
| References |
| Molecular Formula |
C37H36CLF5N2O5S
|
|---|---|
| Molecular Weight |
751.202165603638
|
| Exact Mass |
750.195
|
| CAS # |
1834571-82-2
|
| Related CAS # |
1834571-82-2;
|
| PubChem CID |
154701370
|
| Appearance |
Off-white to brown solid powder
|
| LogP |
9.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
51
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NMQUSJQZQWKQBL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H36ClF5N2O5S/c1-36(2,3)24-15-22(16-25(17-24)37(4,5)6)19-45(27-13-9-23(10-14-27)35(47)48)28(46)20-44(18-21-7-11-26(38)12-8-21)51(49,50)34-32(42)30(40)29(39)31(41)33(34)43/h7-17H,18-20H2,1-6H3,(H,47,48)
|
| Chemical Name |
4-(2-((N-(4-chlorobenzyl)-2,3,4,5,6-pentafluorophenyl)sulfonamido)-N-(3,5-di-tert-butylbenzyl)acetamido)benzoic acid
|
| Synonyms |
AC4130 AC-4130 AC4-130 AC-4-130
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~133.12 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3312 mL | 6.6560 mL | 13.3120 mL | |
| 5 mM | 0.2662 mL | 1.3312 mL | 2.6624 mL | |
| 10 mM | 0.1331 mL | 0.6656 mL | 1.3312 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
